Grapefruit's Bitter Taste Holds Sweet Promise for Diabetes Therapy.
A team of researchers from the Hebrew University of Jerusalem and Massachusetts General Hospital (MGH) report that naringenin activates a family of small proteins, called nuclear receptors, causing the liver to break down fatty acids. In fact, the compound seems to mimic the actions of other drugs, such as the lipid-lowering Fenofibrate and the anti-diabetic Rosiglitazone, offering the advantages of both. If the results of this study extend to human patients, this dietary supplement could become a staple in the treatment of hyperlipidemia, type-2 diabetes, and perhaps metabolic syndrome. "It is a fascinating find," said Yaakov Nahmias, PhD, of the Hebrew University of Jerusalem the paper's senior author. "We show the mechanism by which naringenin increases two important pharmaceutical targets, PPAR? and PPAR?, while blocking a third, LXR?. The results are similar to those induced by long periods of fasting."The liver is the main organ responsible for the regulation of carbohydrate and lipid levels in the blood. Following a meal, the blood is flushed with sugars, which activate LXR?, causing the liver to create fatty acids for long-term storage. During fasting, the process is reversed; fatty acids are released by fat cells, activate PPAR? in the liver, and are broken down to ketones. A similar process, involving PPAR?, increases sensitivity to insulin."It is a process which is similar to the Atkins diet, without many of the side effects," said Martin L. Yarmush, MD, PhD, director of the MGH Center for Engineering in Medicine and one of the paper's authors."The liver behaves as if fasting, breaking down fatty acids instead of carbohydrates." Yarmush is the Helen Andrus Benedict Professor of Surgery and Bioengineering at Harvard Medical School."Dual PPAR? and PPAR? agonists, like naringenin, were long sought after by the pharmaceutical industry," said Nahmias, "but their development was plagued by safety concerns. Remarkably, naringenin is a dietary supplement with a clear safety record. Evidence suggests it might actually protect the liver from damage."Grapefruit's bitter taste is caused the presence of the flavonoid naringin, which is broken down in the gut into naringenin. Earlier evidence has shown the compound has cholesterol lowering properties and may ameliorate some of the symptoms associated with diabetes. The researchers demonstrated that the compound activates PPAR? and PPAR? by dramatically increasing the levels of a co-activator peptide of both, called PGC1?. At the same time, naringenin bound directly to LXR?, blocking its activation. These effects culminated with increased fatty acid oxidation and the inhibition of vLDL ('bad cholesterol') production.
2006 Fars News Agency. All rights reserved
Provided by Syndigate.info an Albawaba.com company
|Printer friendly Cite/link Email Feedback|
|Publication:||FARS News Agency|
|Date:||Aug 26, 2010|
|Previous Article:||Sea Level to Rise Even with Aggressive Geo-Engineering Schemes.|
|Next Article:||Nano-Vehicle Delivers Chemotherapy Treatments on Target.|